CSPC Pharmaceutical (HKG:1093) obtained approval to conduct a clinical trial of its SYH2046 tablets in China from the country's National Medical Products Administration, a Friday filing with the Hong Kong bourse said.
The indication for the trial approval is heart failure after acute myocardial infarction.
Preclinical studies have shown the drug to improve cardiac function and reduce adverse cardiac remodeling in disease animal models with a better safety profile.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。